Melatonin down-regulates MDM2 gene expression and enhances p53 acetylation in MCF-7 cells

Journal of Pineal Research

Volumn 57, Issue 1, 2014, Pages 120-129

  Proietti, Sara ^a   Cucina, Alessandra ^a   Dobrowolny, Gabriella ^a,b   D'Anselmi, Fabrizio ^a   Dinicola, Simona ^a   Masiello, Maria Grazia ^a   Pasqualato, Alessia ^a   Palombo, Alessandro ^a,c   Morini, Veronica ^a   Reiter, Russel J ^d   Bizzarri, Mariano ^e  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

AkT; MDM2; MDMX; melatonin; p300; p53 acetylation; Sirt1

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; E1A ASSOCIATED P300 PROTEIN; MELATONIN; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; PROTEIN P85; SIRT1 PROTEIN, HUMAN; SIRTUIN 1;

ACETYLATION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CARCINOMA CELL; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; DENSITOMETRY; DRUG EFFECTS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; MCF 7 CELL LINE; METABOLISM;

ACETYLATION; APOPTOSIS; DENSITOMETRY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MCF-7 CELLS; MELATONIN; PROTO-ONCOGENE PROTEINS C-MDM2; SIRTUIN 1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84904500796     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12150     Document Type: Article

References (57)

1. Bizzarri M, Proietti S, Cucina A, et al. Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opin Ther Targets 2013; 17: 1483-1496.
2. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, et al. Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem 2010; 17: 4462-4481.
3. Mills E, Wu P, Seely D, et al. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res 2005; 39: 360-366.
4. Reiter RJ, Tan DX, Manchester LC, et al. Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv Med Sci 2007; 52: 11-28.
5. Proietti S, Cucina A, Reiter RJ, et al. Molecular mechanisms of melatonin's inhibitory actions on breast cancers. Cell Mol Life Sci 2013; 70: 2139-2157.
6. Mediavilla MD, Cos S, Sánchez-Barcelõ EJ,. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci 1999; 65: 415-420.
7. Meek DW,. The p53 response to DNA damage. DNA Repair 2004; 3: 1049-1056.
8. Toledo F, Wahl GM,. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6: 909-923.
9. Xirodimas DP, Stephen CW, Lane DP,. Co-compartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp Cell Res 2001; 270: 66-77.
10. Roth J, Dobbelstein M, Freedman DA, et al. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J 1998; 17: 554-564.
11. Ito A, Kawaguchi Y, Lai CH, et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002; 21: 6236-6245.
12. Tang Y, Zhao W, Chen Y, et al. Acetylation is indispensable for p53 activation. Cell 2008; 133: 612-626.
13. Grossman SR,. p300/CBP/p53 interaction and regulation of the p53 response. Eur J Biochem 2001; 268: 2773-2778.
14. Bond GL, Hu W, Levine AJ,. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 2005; 5: 3-8.
15. Lohrum MA, Ludwig RL, Kubbutat MH, et al. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003; 3: 577-587.
16. Mayo LD, Donner DB,. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001; 98: 11598-11603.
17. de Rozieres S, Maya R, Oren M, et al. The loss of mdm2 induces p53 mediated apoptosis. Oncogene 2000; 19: 1691-1697.
18. Chène P,. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003; 3: 102-109.
19. Yang Y, Ludwig RL, Jensen JP, et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005; 7: 547-559.
20. Li M, Zhang Z, Hill DL, et al. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 2007; 67: 1988-1996.
21. Li M, Zhang Z, Hill DL, et al. Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res 2005; 65: 8200-8208.
22. Cucina A, Proietti S, D'anselmi F, et al. Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. J Pineal Res 2009; 46: 172-180.
23. Proietti S, Cucina A, D'anselmi F, et al. Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells. J Pineal Res 2011; 50: 150-158.
24. Fakharzadeh SS, Trusko SP, George DL,. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991; 10: 1565-1569.
25. Montes de Oca Luna R, WAGNER DS, LOZANO G,. Rescue of early embryonic lethality in MDM2-deficient mice by deletion of p53. Nature 1995; 378: 203-206.
26. Momand J, Wu HH, Dasgupta G,. MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000; 242: 15-29.
27. Reifenberger G, Liu L, Ichimura K, et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736-2739.
28. Daujat S, Neel H, Piette J,. MDM2: life without p53. Trends Genet 2001; 17: 459-464.
29. Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
30. Wang J, Xiao X, Zhang Y, et al. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res 2012; 53: 77-90.
31. Zhou BP, Liao Y, Xia W, et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001; 3: 973-982.
32. Vashamanin VA, Androphy EJ,. Immortalization of human mammary epithelial cells is associated with inactivation of the p14ARF-p53.Pathway. Mol Cell Biol Mar 2004; 24: 2144-2152.
33. van Ham RCA, van der Houven W, van Oordt G, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 1996; 15: 5349-5357.
34. Wade M, Wang YV, Wahl GM,. The p53 orchestra: MDM2 and MDMX set the tone. Trends Cell Biol 2010; 20: 299-309.
35. Stad R, Little NA, Xirodimas DP, et al. MDMX stabilizes p53 and MDM2 via two mechanisms. EMBO Rep 2001; 2: 1029-1034.
36. Jackson MW, Berberich SJ,. MDMX protects p53 from MDM2-mediated degradation. Mol Cell Biol 2000; 20: 1001-1007.
37. Gu J, Kawai H, Nie L, et al. Mutual dependence of mdm2 and mdmx in their functional inactivation of p53. J Biol Chem 2002; 277: 19251-19254.
38. Marine JC, Dyer MA, Jochemsen AG,. MDMX: from bench to bedside. J Cell Sci 2007; 120: 371-378.
39. Toledo F, Krummel KA, Lee CJ, et al. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 2006; 9: 273-285.
40. Touqan N, Diggle CP, Verghese ET, et al. An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomas. BMC Clin Pathol 2013; 13: 32-41.
41. Giordano A, Avantaggiati ML,. p300 and CBP: partners for life and death. J Cell Physiol 1999; 181: 218-230.
42. Banerjee S, Arif M, Rakshit T, et al. Structural features of human histone acetyltransferase p300 and its complex with p53. FEBS Lett 2012; 586: 3793-3798.
43. Grossman SR, Perez M, Kung AL, et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell 1998; 2: 405-415.
44. Ito A, Lai CH, Zhao X, et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 2001; 20: 1331-1340.
45. Wang X, Taplick JT, Geva N, et al. Inhibition of p53 degradation by mdm2 acetylation. FEBS Lett 2004; 561: 195-201.
46. Kawai H, Nie L, Wiederschain D, et al. Dual role of p300 in the regulation of p53 stability. J Biol Chem 2001; 276: 45928-45932.
47. Gayther SA, Batley SJ, Linger L, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000; 24: 300-303.
48. Bouras T, Fu M, Sauve AA, et al. SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J Biol Chem 2005; 280: 10264-71026.
49. Tyteca S, Legube G, Trouche D,. To die or not to die: A HAT Trick. Mol Cell 2006; 24: 807-812.
50. van Leeuwen I, Lain S,. Sirtuins and p53. Adv Cancer Res 2009; 102: 171-195.
51. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2 alpha promotes cell survival under stress. Cell 2001; 107: 137-148.
52. Kobet E, Zeng X, Zhu Y, et al. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc Natl Acad Sci USA 2000; 97: 12547-12552.
53. Yuan ZM, Huang Y, Ishiko T, et al. Role for p300 in Stabilization of p53 in the response to DNA Damage. J Biol Chem 1999; 274: 1883-1886.
54. Harper JW, Adami GR, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
55. Gopalakrishna NL, Chin SF, Ozdag H, et al. p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc Natl Acad Sci USA 2004; 101: 7386-7391.
56. Hill SM, Blask DE,. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 1988; 48: 6121-6126.
57. Vousden KH,. Switching from life to death: the Miz-ing link between Myc and p53. Cancer Cell 2002; 2: 351-352.